Leukemia Therapeutics by Technology, Share, Size, Segmentation, Revenue Analysis Forecast 2028

Market Overview

The global leukemia therapeutics market size is projected to reach USD 27.78 billion by 2027, exhibiting a CAGR of 8.1% during the forecast period. The increasing demand for enhanced treatments for blood cancers amid the COVID-19 pandemic will accelerate the market, states Fortune Business Insights™ in its report, titled “Leukemia Therapeutics Market Size, Share & Industry Analysis, By Type of Leukemia (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), and Others), By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Route of Administration (Oral Mode and Injectable Mode), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, and Others), and Regional Forecast, 2020-2027”.

Request for Sample Report PDF @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/leukemia-therapeutics-market-104754

Cancer patients are at a heightened risk of contracting the coronavirus and likely to experience severe effects of the infection due to their weakened immune systems. According to a study conducted by the UK Coronavirus Cancer Monitoring Project (UKCCMP), patients with leukemia, multiple myeloma, and lymphoma are highly susceptible to COVID-19 and leukemia patients have twice the chance of dying from the virus. The study found that patients with blood cancer are 57% more likely to experience severe symptoms of COVID-19 than patients with other types of cancers. Given these and other similar findings, the demand for leukemia therapeutics has been soaring during the COVID-19 pandemic, with market players reporting increased sales. Bristol-Myers Squibb, for instance, announced that the sales of Sprycel, its treatment for chronic myeloid leukemia (CML) jumped 14% to USD 521 million in the first quarter of 2020. However, the disruption in the medical supply chain will lead the market to register a lower growth rate of 6.2% and touch a value of USD 16.15 billion in 2020.

As per the report findings, the estimated value of the global market stood at USD 15.21 billion in 2019. The main highlights of the report include:

Calculated estimations about the upcoming trends and prospects in the market;
Path-breaking research into the regional dynamics of the market;
Comprehensive study of the factors driving and restraining the market; and
Careful profiling and diagnosis of the key market players and their dominant strategies.
Restraining Factors

Debilitating Side Effects of Chemotherapy May Hinder Market Growth

Chemotherapy is one of the most potent leukemia therapeutics and has emerged as the most powerful and the most commonly recommended treatment for most types of cancers. Chemo drugs are designed to attack and kill fast-growing cells, and since cancer cells proliferate rapidly, these medications speedily eliminate them. However, because chemo medicines travel throughout the body, they end up killing healthy cells, leading to side effects that can considerably weaken the patient, albeit temporarily. For example, chemotherapy can harm the blood cells in the bone marrow, where red blood cells (RBCs) are manufactured. With RBC production disrupted, the patient is likely to experience moderate to severe anemia, which in turn can cause symptoms such as fatigue, lightheadedness, and general weakness. Furthermore, chemo can also harm the production of white blood cells (WBCs), the body’s soldiers that fight infections. As a result, cancer patients become extremely susceptible to infections and even a minor bout of cough & cold can prove detrimental for them. Thus, the known side effects of chemotherapy may hamper the leukemia therapeutics market growth.

Regional Insights

North America to Foster Stable Market Growth Backed by High Healthcare Expenditure

North America is expected to dominate the leukemia therapeutics market share during the forecast period as the USA and Canada have sharply increased their spending on healthcare technologies and infrastructure in the past few decades. Moreover, policymakers in the two countries are taking constant efforts to expand healthcare coverage, especially for cancer patients. In 2019, the region’s market size stood at USD 6.92 billion.

Europe is poised to emerge as the second-largest market for leukemia therapeutics due to the increasing number of leukemia patients in the continent. In the UK, for instance, leukemia accounted for 3% of all cancer cases in the country in 2017, according to Cancer Research UK. The market in Asia Pacific, on the other hand, will experience prolific growth owing to the improving health reimbursement policies in China and India.

Competitive Landscape

Regulatory Support for Innovative Therapies to Raise Market Potential

Key players in this market are enjoying a period of consistent support for their offerings by regulatory bodies such as the US Food and Drug Administration (FDA). Such support will play an instrumental role in managing leukemia symptoms in patients and the criticality of leukemia therapeutics is likely to rise as cancer prevalence grows worldwide.

Industry Developments:

October 2020: The US FDA cleared AbbVie’s VENCLEXTA treatment in combination with azacitidine, or decitabine, or low-dose cytarabine. The therapy is indicated for treating acute myeloid leukemia (AML) in adults aged 75 years and above or those with comorbidities who cannot undergo intensive chemotherapy.
September 2020: Bristol Myers Squibb secured the US FDA’s approval for its Onuregfor the continued treatment of adult patients with AML. The treatment is designed for those patients who have attained the first complete remission or remission with incomplete blood recovery following intensive chemo.

Ask for Customization @ https://www.fortunebusinessinsights.com/enquiry/customization/leukemia-therapeutics-market-104754

List of Key Companies Covered in the Leukemia Therapeutics Market Report:

Sanofi/ Genzyme Corporation (Paris, France)
Hoffmann-La Roche (Basel, Switzerland)
Johnson & Johnson Services, Inc. (New Brunswick, U.S.)
Amgen Inc. (Thousand Oaks, U.S.)
Novartis (Basel, Switzerland)
Takeda Pharmaceutical Co Ltd (Tokyo, Japan)
Bristol-Myers Squibb (New York, U.S.)
AbbVie (North Chicago, U.S.)
Lupin Ltd. (India, Mumbai)
Pfizer Inc. (New York, U.S.)


Table Of Content:

Introduction
Research Scope
Market Segmentation
Research Methodology
Definitions and Assumptions
Executive Summary
Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Key Insights
Pipeline Analysis, Key Players
Prevalence of Leukemia, Key Countries, 2019
Key Industry Developments (Mergers, Acquisition, etc.)
Impact of Covid-19 on the Leukemia Therapeutics Market
Global Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
Key Findings / Summary
Market Analysis, Insights and Forecast – By Type of Leukemia
Chronic Myeloid Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Acute Lymphocytic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Others
Market Analysis, Insights and Forecast – By Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Others
Market Analysis, Insights and Forecast – By Route of Administration
Injectable Mode
Oral Mode
Market Analysis, Insights and Forecast – By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Market Analysis, Insights and Forecast – By Region
North America
Europe
Asia pacific
Latin America
Middle East & Africa
North America Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
Key Findings / Summary
Market Analysis – By Type of Leukemia
Chronic Myeloid Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Acute Lymphocytic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Others
Market Analysis – By Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Others
Market Analysis – By Route of Administration
Injectable Mode
Oral Mode
Market Analysis – By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Market Analysis – By Country
S.
Canada
Europe Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
Key Findings / Summary
Market Analysis – By Type of Leukemia
Chronic Myeloid Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Acute Lymphocytic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Others
Market Analysis – By Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Others
Market Analysis – By Route of Administration
Injectable Mode
Oral Mode
Market Analysis – By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Market Analysis – By Country/Sub-Region
K.
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
Key Findings / Summary
Market Analysis – By Type of Leukemia
Chronic Myeloid Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Acute Lymphocytic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Others
Market Analysis – By Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Others
Market Analysis – By Route of Administration
Injectable Mode
Oral Mode
Market Analysis – By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Market Analysis – By Country/Sub-Region
Japan
China
India
Australia
Rest of Asia Pacific
Latin America Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
Key Findings / Summary
Market Analysis – By Type of Leukemia
Chronic Myeloid Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Acute Lymphocytic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Others
Market Analysis – By Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Others
Market Analysis – By Route of Administration
Injectable Mode
Oral Mode
Market Analysis – By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Market Analysis – By Country/Sub-Region
Brazil
Mexico
Rest of Latin America
Middle East & Africa Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
Key Findings / Summary
Market Analysis – By Type of Leukemia
Chronic Myeloid Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Acute Lymphocytic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Others
Market Analysis – By Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Others
Market Analysis – By Route of Administration
Injectable Mode
Oral Mode
Market Analysis – By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Market Analysis – By Country/Sub-Region
GCC Countries
South Africa
Rest of Middle East & Africa
Competitive Analysis
Key Industry Developments
Global Market Share Analysis (2019)
Competition Dashboard
Comparative Analysis – Major Players
Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
Pfizer Inc.
Novartis
Sanofi/ Genzyme Corporation
Lupin Ltd.
Amgen Inc.
AbbVie
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb
Hoffmann-La Roche
Takeda Pharmaceutical Co Ltd
Sanofi/ Genzyme Corporation


Continued. . .

Related Article @

https://marketresearchreportsfbi.wordpress.com/2021/11/08/autotransfusion-devices-market-by-technology-share-size-segmentation-revenue-analysis-forecast-2028/

https://www.theexpresswire.com/pressrelease/US-C-arms-Market-to-Reach-11461-Million-With-CAGR-44-During-Forecast-2021-2028_14682333

NOTE: Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. We aim to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

This release was published on openPR.